Updated: Mon, 10/07/2024 - 21:42

From Saturday, Oct. 5 through Tuesday, Oct. 8, the Downtown and Macdonald Campuses will be open only to McGill students, employees and essential visitors. Many classes will be held online. Remote work required where possible. See Campus Public Safety website for details.


Du samedi 5 octobre au mardi 8 octobre, le campus du centre-ville et le campus Macdonald ne seront accessibles qu’aux étudiants et aux membres du personnel de l’Université McGill, ainsi qu’aux visiteurs essentiels. De nombreux cours auront lieu en ligne. Le personnel devra travailler à distance, si possible. Voir le site Web de la Direction de la protection et de la prévention pour plus de détails.

Event

Seminar | Protas - Smarter Trials for Better Health

Thursday, September 19, 2024 11:00to12:30
Room 6001, Genome Building, Montreal, QC, CA

Join D2R and the Victor Phillip Dahdaleh Institute of Genomic Medicine for this hybrid seminar with Professor Richard Haynes from Oxford University where he will present how Protas is changing the face of clinical trials.

Randomized trials remain the best methodology to assess the efficacy and safety of treatments, BUT they are facing a crisis. Rising regulatory burden and costs mean that some effective treatments are either not developed or are only developed for a narrow indication, preventing their full benefits from being realized. Conversely, less effective treatments may not be identified, or worse, their hazards may go unrecognized. Protas, a not-for-profit organization, intends to combine smart trial design and delivery, effective use of data and technology and collaborative policy development to address this challenge and improve population health.

Agenda

11:00am-11:05am Welcome
By Mark Lathrop, D2R Scientific Director
11:05am-12:05pm Protas, Smarter Trials for Better Health
By Richard Haynes, Professor of Renal Medicine and Clinical Trials,
Oxford University
12:05pm-12:25pm Q&A
12:25pm-12:30pm Closing Remarks

About the Speaker:

Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to Oxford University’s Clinical Trial Service Unit for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Alongside his clinical practice, his research focusses on large-scale streamlined trials. He has delivered trials in cardiovascular disease and was co-principal investigator of EMPA-KIDNEY which demonstrated the efficacy and safety of empagliflozin in people with CKD. He also led his trials unit delivery of the RECOVERY trial which was the largest trial of treatments for covid-19. He now combines his research at CTSU with his role as Chief Scientist at Protas.

Reserve Your Spot Now!

Be part of this transformative discussion on the future of medical trials.

RSVP by Tuesday September 17:

Want to attend in-person? Reserve your spot by emailing D2R.comms [at] mcgill.ca

Confirmation emails will be provided to registered participants a few days before the event.

Back to top